On July 7, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended to suspend broad spectrum intravenous use of linear gadolinium agents except for select indication of liver imaging.
The PRAC’s recommendation applies to Europe only and is not
https://www.genewsroom.com/press-releases/message-our-customers-about-pharmacovigilance-risk-assessment-committee